Free Trial

Bluejay Diagnostics Q2 2024 Earnings Report

Bluejay Diagnostics logo
$3.84 -0.06 (-1.54%)
(As of 12/20/2024 05:40 PM ET)

Bluejay Diagnostics EPS Results

Actual EPS
-$256.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bluejay Diagnostics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Bluejay Diagnostics Earnings Headlines

Bluejay Diagnostics Inc trading halted, news pending
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Bluejay Diagnostics announces 1-for-50 reverse stock split
Bluejay Diagnostics Announces Reverse Stock Split
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX), a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

View Bluejay Diagnostics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings